To view this email as a web page, click here.

 
Dermatology Times
Verrica’s solution for common warts
Dr. Matt Davidson, Ph.D., wanted to find an effective and affordable treatment for the embarrassing recurring warts on his hands. Who knew this affliction would lead him to become one of the youngest pharmaceutical company pioneers in the country. Read his story here.
ADVERTISEMENT
 
Dermatology Times
Sarecycline for moderate-to-severe acne
The Food and Drug Administration (FDA) approved sarecycline (Seysara, Almirall, S.A.) in October for the treatment of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older, according to a company news release.
ADVERTISEMENT
 
FDA-approved cosmetics
Some believe that all skincare products should be regulated by the FDA, but is it really necessary? Read this dermatologist’s opinion here.
 
Psoriasis Resource Center
 
High efficacy shown in self-inject psoriasis biologic
Patient-provider disconnect in psoriasis
The connection between multiple sclerosis and psoriasis
 
From Our Latest Issue
 
Dermatology Times cover
Market competition impacts topical generic medication pricing
 
First approved biologic in dermatology to carry suffix
 
European data protection regulation impacts U.S. patient privacy
 
ADVERTISEMENT
“Approach every single acne patient as a patient who can potentially scar.”
Approximately 40% of acne patients have scars — and scarring can occur in any severity of acne. Watch this video to learn more about how a decrease in acne lesions can lead to a decrease in acne scars, even in moderate to severe acne patients.
 
JOB OPPORTUNITIES
 
 
ADVERTISEMENT
The Cosmetic Professional's Guide to Patient Financing
Would you like to grow your revenue while saving thousands in provider fees? Download the Ultimate Guide to Patient Financing to learn how! Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.